Cited by 1,650HER2/EGFR in Cancer ResearchProtein Kinase Regulation and GTPase SignalingLung Cancer Treatments and Mutations

The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.

An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor

Open access

Zhang, Xuewu, Gureasko, Jodi, Shen, Kui, Cole, Philip A., Kuriyan, John·2006·Cell

DOI 10.1016/j.cell.2006.05.013

Open this paper in CoChat — free account Open PDF

Abstract

The mechanism by which the epidermal growth factor receptor (EGFR) is activated upon dimerization has eluded definition. We find that the EGFR kinase domain can be activated by increasing its local concentration or by mutating a leucine (L834R) in the activation loop, the phosphorylation of which is not required for activation. This suggests that the kinase domain is intrinsically autoinhibited, and an intermolecular interaction promotes its activation. Using further mutational analysis and crystallography we demonstrate that the autoinhibited conformation of the EGFR kinase domain resembles that of Src and cyclin-dependent kinases (CDKs). EGFR activation results from the formation of an asymmetric dimer in which the C-terminal lobe of one kinase domain plays a role analogous to that of cyclin in activated CDK/cyclin complexes. The CDK/cyclin-like complex formed by two kinase domains thus explains the activation of EGFR-family receptors by homo- or heterodimerization.

Integrity signals

Registry

Crossref · 10.1016/j.cell.2006.05.013

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377
The Conformational Plasticity of Protein Kinases
Huse, M., & Kuriyan, J. (2002) · Cell · doi:10.1016/s0092-8674(02)00741-9 · Cited by 1,760
Self-citation
Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways
Sordella, R., Bell, D. W., Haber, D. A., & Settleman, J. E. (2004) · Science · doi:10.1126/science.1101637 · Cited by 1,605
Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor
Stamos, J. L., Sliwkowski, M. X., & Eigenbrot, C. W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207135200 · Cited by 1,594
Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex
Jeffrey, P. D., Russo, A. A., Polyák, K., Gibbs, E., Hurwitz, J., Massagué, J., & Pavletich, N. P. (1995) · Nature · doi:10.1038/376313a0 · Cited by 1,455
Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains
Ogiso, H., Ishitani, R., Nureki, O., Fukai, S., Yamanaka, M., Kim, J.-H., Saito, K., Sakamoto, A., Inoue, M., Shirouzu, M., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00963-7 · Cited by 1,227

Show all 42 references

Sorted by citations

Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
Yun, C.-H., Mengwasser, K. E., Toms, A. V., Woo, M. S., Greulich, H., Wong, K.-K., Meyerson, M., & Eck, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709662105 · Cited by 2,118
Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Wee, P., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050052 · Cited by 2,027
HSP90 at the hub of protein homeostasis: emerging mechanistic insights
Taipale, M., Jarosz, D. F., & Lindquist, S. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2918 · Cited by 1,818
Emerging functions of the EGFR in cancer
Sigismund, S., Avanzato, D., & Lanzetti, L. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12155 · Cited by 1,552
The ErbB/HER family of protein-tyrosine kinases and cancer
Roskoski, R. J. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.11.002 · Cited by 1,408
Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity
Yun, C.-H., Boggon, T. J., Li, Y., Woo, M. S., Greulich, H., Meyerson, M., & Eck, M. J. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.12.017 · Cited by 1,192
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
Baselga, J. M., & Swain, S. M. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2656 · Cited by 1,170
Mechanisms of receptor tyrosine kinase activation in cancer
Du, Z., & Lovly, C. M. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0782-4 · Cited by 1,066
The ERBB network: at last, cancer therapy meets systems biology
Yarden, Y., & Pines, G. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3309 · Cited by 1,031
Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
Gazdar, A. F. (2009) · Oncogene · doi:10.1038/onc.2009.198 · Cited by 991
EGFR Mutations and Lung Cancer
Santos, G. D. C., Shepherd, F. A., & Tsao, M. (2011) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130206 · Cited by 964
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
Jia, Y., Yun, C., Park, E., Ercan, D., Manuia, M., Juarez, J., Xu, C., Rhee, K., Chen, T., Zhang, H., et al. (2016) · Nature · doi:10.1038/nature17960 · Cited by 954
The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy
Scaltriti, M., & Baselga, J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1554 · Cited by 913
Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
Bose, R., Kavuri, S. M., Searleman, A. C., Shen, W., Shen, D., Koboldt, D. C., Monsey, J. D., Goel, N. J., Aronson, A. B., Li, S., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0349 · Cited by 886
The Arabidopsis NPR1 Protein Is a Receptor for the Plant Defense Hormone Salicylic Acid
Wu, Y., Zhang, D., Chu, J. Y., Boyle, P., Wang, Y., Brindle, I. D., Luca, V. D., & Després, C. (2012) · Cell Reports · doi:10.1016/j.celrep.2012.05.008 · Cited by 884
Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker
Solca, F., Dahl, G., Zoephel, A., Bader, G., Sanderson, M., Klein, C., Kraemer, O., Himmelsbach, F., Haaksma, E., & Adolf, G. R. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.197756 · Cited by 865
EGF receptor trafficking: consequences for signaling and cancer
Tomas, A., Futter, C. E., & Eden, E. R. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2013.11.002 · Cited by 779
The epidermal growth factor receptor family: Biology driving targeted therapeutics
Wieduwilt, M. J., & Moasser, M. M. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-7440-8 · Cited by 791
Regulation of RAF protein kinases in ERK signalling
Lavoie, H., & Therrien, M. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3979 · Cited by 702
Role of PINK1 Binding to the TOM Complex and Alternate Intracellular Membranes in Recruitment and Activation of the E3 Ligase Parkin
Lazarou, M., Jin, S. M., Kane, L. A., & Youle, R. J. (2012) · Developmental Cell · doi:10.1016/j.devcel.2011.12.014 · Cited by 670
The unfolded protein response signals through high-order assembly of Ire1
Korennykh, A. V., Egea, P. F., Korostelev, A. A., Finer-Moore, J., Zhang, C., Shokat, K. M., Stroud, R. M., & Walter, P. (2009) · Nature · doi:10.1038/nature07661 · Cited by 656
Membrane lipid saturation activates endoplasmic reticulum unfolded protein response transducers through their transmembrane domains
Volmer, R., van der Ploeg, K., & Ron, D. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217611110 · Cited by 668
EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications
Yasuda, H., Kobayashi, S., & Costa, D. B. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70129-2 · Cited by 610
Mechanism for Activation of the EGF Receptor Catalytic Domain by the Juxtamembrane Segment
Jura, N., Endres, N., Engel, K., Deindl, S., Das, R., Lamers, M. H., Wemmer, D. E., Zhang, X., & Kuriyan, J. (2009) · Cell · doi:10.1016/j.cell.2009.04.025 · Cited by 609
Self-citation
Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer
Yasuda, H., Park, E., Yun, C.-H., Sng, N. J., Lucena-Araujo, A. R., Yeo, W.-L., Huberman, M. S., Cohen, D. W., Nakayama, S., Ishioka, K., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007205 · Cited by 571
Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer
Mitsudomi, T., & Yatabe, Y. (2009) · FEBS Journal · doi:10.1111/j.1742-4658.2009.07448.x · Cited by 560
Emerging roles of pseudokinases
Boudeau, J., Miranda‐Saavedra, D., Barton, G. J., & Alessi, D. R. (2006) · Trends in Cell Biology · doi:10.1016/j.tcb.2006.07.003 · Cited by 559
Spatial control of EGF receptor activation by reversible dimerization on living cells
Chung, I., Akita, R. W., VANDLEN, R. L., Toomre, D. K., Schlessinger, J., & Mellman, I. (2010) · Nature · doi:10.1038/nature08827 · Cited by 538
Receptor tyrosine kinases: mechanisms of activation and signaling
Hubbard, S. R., & Miller, W. T. (2007) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2007.02.010 · Cited by 565
Roles for Growth Factors in Cancer Progression
Witsch, E., Sela, M., & Yarden, Y. (2010) · Physiology · doi:10.1152/physiol.00045.2009 · Cited by 568
Architecture and Membrane Interactions of the EGF Receptor
Arkhipov, A. S., Shan, Y., Das, R., Endres, N., Eastwood, M. P., Wemmer, D. E., Kuriyan, J., & Shaw, D. E. (2013) · Cell · doi:10.1016/j.cell.2012.12.030 · Cited by 507
Self-citation
Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers
Roskoski, R. J. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.11.014 · Cited by 502
Conformational Coupling across the Plasma Membrane in Activation of the EGF Receptor
Endres, N., Das, R., Smith, A. W., Arkhipov, A. S., Kovács, E., Huang, Y., Pelton, J. G., Shan, Y., Shaw, D. E., Wemmer, D. E., et al. (2013) · Cell · doi:10.1016/j.cell.2012.12.032 · Cited by 509
Self-citation
A dimerization-dependent mechanism drives RAF catalytic activation
Rajakulendran, T., Sahmi, M., Lefrançois, M., Sicheri, F., & Therrien, M. (2009) · Nature · doi:10.1038/nature08314 · Cited by 505
The EGFR Family: Not So Prototypical Receptor Tyrosine KinasesPreprint
Lemmon, M. A., Lemmon, M. A., & Ferguson, K. M. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020768 · Cited by 472
ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation
Shi, F., Telesco, S., Liu, Y., Radhakrishnan, R., & Lemmon, M. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002753107 · Cited by 485
Regulation of MAPKs by growth factors and receptor tyrosine kinases
Katz, M., Amit, I., & Yarden, Y. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2007.01.002 · Cited by 490
Structural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 Protein
Aertgeerts, K., Skene, R. J., Yano, J. K., Sang, B., Zou, H., Snell, G., Jennings, A. J., Iwamoto, K., Habuka, N., Hirokawa, A., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.206193 · Cited by 448
Targeted Therapy and Checkpoint Immunotherapy in Lung Cancer
Ruiz‐Cordero, R., & Devine, W. P. (2020) · Surgical pathology clinics · doi:10.1016/j.path.2019.11.002 · Cited by 463
Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity
Scaltriti, M., Verma, C. S., Guzmán, M., Jimenez, J., Parra, J.-L., Pedersen, K., Smith, D. J., Landolfi, S., y Cajal, S. R., Arribas, J., et al. (2008) · Oncogene · doi:10.1038/onc.2008.432 · Cited by 440
Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain
Park, J. H., Liu, Y., Lemmon, M. A., & Radhakrishnan, R. (2012) · Biochemical Journal · doi:10.1042/bj20121513 · Cited by 432
The Role of Protein Loops and Linkers in Conformational Dynamics and Allostery
Papaleo, E., Saladino, G., Lambrughi, M., Lindorff‐Larsen, K., Gervasio, F. L., & Nussinov, R. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00623 · Cited by 434
The Structural Basis for Control of Eukaryotic Protein Kinases
Endicott, J., Noble, M. E. M., & Johnson, L. N. (2012) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-052410-090317 · Cited by 440
Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib
Cataldo, V. D., Gibbons, D. L., Perez-Soler, R., & Quintás‐Cardama, A. (2011) · New England Journal of Medicine · doi:10.1056/nejmct0807960 · Cited by 429
Activation of tyrosine kinases by mutation of the gatekeeper threonine
Azam, M., Seeliger, M. A., Gray, N. S., Kuriyan, J., & Daley, G. Q. (2008) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1486 · Cited by 416
Self-citation
The EGF receptor family: spearheading a merger of signaling and therapeutics
Bublil, E. M., & Yarden, Y. (2007) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2007.02.008 · Cited by 398
The Evolution of Protein Kinase Inhibitors from Antagonists to Agonists of Cellular Signaling
Dar, A. C., & Shokat, K. M. (2011) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-090308-173656 · Cited by 400
The origin of protein interactions and allostery in colocalization
Kuriyan, J., & Eisenberg, D. S. (2007) · Nature · doi:10.1038/nature06524 · Cited by 380
Self-citation
Antitumor Activity and Pharmacology of a Selective Focal Adhesion Kinase Inhibitor, PF-562,271
Roberts, W. G., Ung, E. J., Whalen, P. M., Cooper, B. A., Hulford, C. A., Autry, C., Richter, D., Emerson, E., Lin, J., Kath, J. C., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5155 · Cited by 381
ErbB receptors: new insights on mechanisms and biology
Linggi, B. E., & CARPENTER, G. (2006) · Trends in Cell Biology · doi:10.1016/j.tcb.2006.10.008 · Cited by 386
Rational Approaches to Improving Selectivity in Drug Design
Huggins, D. J., Sherman, W., & Tidor, B. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm2010332 · Cited by 390
The epidermal growth factor receptor variant III ( EGFR v III ): where wild things are altered
Gan, H. K., Cvrljevic, A. N., & Johns, T. G. (2013) · FEBS Journal · doi:10.1111/febs.12393 · Cited by 394
A Structural Perspective on the Regulation of the Epidermal Growth Factor Receptor
Kovács, E., Zorn, J. A., Huang, Y., Barros, T. F., & Kuriyan, J. (2015) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060614-034402 · Cited by 371
Self-citation
Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer
Regales, L., Gong, Y., Shen, R., de Stanchina, E., Vivanco, I., Goel, A. J., Koutcher, J. A., Spassova, M. K., Ouerfelli, O., Mellinghoff, I. K., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38746 · Cited by 376
A Glimpse of Structural Biology through X-Ray Crystallography
Shi, Y. (2014) · Cell · doi:10.1016/j.cell.2014.10.051 · Cited by 382
Structure-Based View of Epidermal Growth Factor Receptor Regulation
Ferguson, K. M. (2008) · Annual Review of Biophysics · doi:10.1146/annurev.biophys.37.032807.125829 · Cited by 368
EGFR signaling pathway as therapeutic target in human cancers
Levantini, E., Maroni, G., Re, M. D., & Tenen, D. G. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.04.002 · Cited by 390
Oncogenic Mutations Counteract Intrinsic Disorder in the EGFR Kinase and Promote Receptor Dimerization
Shan, Y., Eastwood, M. P., Zhang, X., Kim, E. T., Arkhipov, A. S., Dror, R. O., Jumper, J., Kuriyan, J., & Shaw, D. E. (2012) · Cell · doi:10.1016/j.cell.2012.02.063 · Cited by 360
Self-citation
Update on Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer
Riely, G. J., Politi, K. A., Miller, V. A., & Pao, W. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0658 · Cited by 363
Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface
Zhang, X., Pickin, K. A., Bose, R., Jura, N., Cole, P. A., & Kuriyan, J. (2007) · Nature · doi:10.1038/nature05998 · Cited by 357
Self-citation
The structure of P‐TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation
Baumli, S., Lolli, G., Lowe, E. D., Troiani, S., Rusconi, L., Bullock, A. N., Debreczeni, J. E., Knapp, S., & Johnson, L. N. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.121 · Cited by 357
Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor
To, C., Jang, J., Chen, T., Park, E., Mushajiang, M., Clercq, D. J. H. D., Xu, M., Wang, S., Cameron, M. D., Heppner, D. E., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0903 · Cited by 351
Structure and mechanism of human DNA polymerase η
Biertümpfel, C., Zhao, Y., Kondo, Y., Ramón‐Maiques, S., Gregory, M., Lee, J. Y., Masutani, C., Lehmann, A. R., Hanaoka, F., & Yang, W. (2010) · Nature · doi:10.1038/nature09196 · Cited by 349
Molecular Mechanisms of Disease-Causing Missense Mutations
Stefl, S. K., Nishi, H., Petukh, M. G., Panchenko, A. R., & Alexov, E. (2013) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.07.014 · Cited by 345
Receptor Tyrosine Kinases: Legacy of the First Two DecadesPreprint
Schlessinger, J. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a008912 · Cited by 354
Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3
Jura, N., Shan, Y., Cao, X., Shaw, D. E., & Kuriyan, J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912101106 · Cited by 338
Self-citation
Expression and Function of the Epidermal Growth Factor Receptor in Physiology and Disease
Chen, J., Zeng, F., Forrester, S. J., Eguchi, S., Zhang, M., & Harris, R. C. (2016) · Physiological Reviews · doi:10.1152/physrev.00030.2015 · Cited by 336
The many faces of calmodulin in cell proliferation, programmed cell death, autophagy, and cancer
Berchtold, M. W., & Villalobo, A. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.10.021 · Cited by 322
The Juxtamembrane Region of the EGF Receptor Functions as an Activation Domain
Brewer, M. R., Choi, S. H., Alvarado, D., Moravcevic, K., Pozzi, A., Lemmon, M. A., & Carpenter, G. F. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.04.034 · Cited by 323
The Structural Basis of Ligand Perception and Signal Activation by Receptor Kinases
Hohmann, U., Lau, K., & Hothorn, M. (2017) · Annual Review of Plant Biology · doi:10.1146/annurev-arplant-042916-040957 · Cited by 302
Structure and Clinical Relevance of the Epidermal Growth Factor Receptor in Human Cancer
Kumar, A., Petri, E. T., Halmos, B., & Boggon, T. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.1178 · Cited by 308
Catalytic Control in the EGF Receptor and Its Connection to General Kinase Regulatory Mechanisms
Jura, N., Zhang, X., Endres, N. F., Seeliger, M. A., Schindler, T., & Kuriyan, J. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.03.004 · Cited by 310
Self-citation
Role of ErbB Receptors in Cancer Cell Migration and Invasion
Appert-Collin, A., Hubert, P., Crémel, G., & Bennasroune, A. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00283 · Cited by 310
Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.
Stewart, E., Tan, S. Z., Liu, G., & Tsao, M. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2014.11.06 · Cited by 314
Structure and Chemical Inhibition of the RET Tyrosine Kinase Domain
Knowles, P. P., Murray‐Rust, J., Kjær, S., Scott, R. P., Hanrahan, S. J., Santoro, M. M., Ibáñez, C. F., & McDonald, N. Q. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605604200 · Cited by 313
Allosteric Activation of Functionally Asymmetric RAF Kinase Dimers
Hu, J., Stites, E. C., Yu, H., Germino, E., Meharena, H. S., Stork, P. A., Kornev, A. P., Taylor, S. S., & Shaw, A. S. (2013) · Cell · doi:10.1016/j.cell.2013.07.046 · Cited by 303
EGFR family: Structure physiology signalling and therapeutic targets †
Burgess, A. W. (2008) · Growth Factors · doi:10.1080/08977190802312844 · Cited by 288
Functional selectivity of EGF family peptide growth factors: Implications for cancer
Wilson, K. J., Gilmore, J. L., Foley, J., Lemmon, M. A., & Riese, D. J. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.11.008 · Cited by 286
Dynamics-Driven Allostery in Protein Kinases
Kornev, A. P., & Taylor, S. S. (2015) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.09.002 · Cited by 289
Tyrosine phosphorylation controls brassinosteroid receptor activation by triggering membrane release of its kinase inhibitorPreprint
Jaillais, Y., Hothorn, M., Belkhadir, Y., Dabi, T., Nimchuk, Z. L., Meyerowitz, E. M., & Chory, J. (2011) · Genes & Development · doi:10.1101/gad.2001911 · Cited by 273
Signalling scaffolds and local organization of cellular behaviour
Langeberg, L. K., & Scott, J. D. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3966 · Cited by 284
ErbB1 dimerization is promoted by domain co-confinement and stabilized by ligand binding
Low-Nam, S. T., Lidke, K. A., Cutler, P. J., Roovers, R. C., Henegouwen, P. M. P. V. B. E., Wilson, B. S., & Lidke, D. S. (2011) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2135 · Cited by 273
Transformable peptide nanoparticles arrest HER2 signalling and cause cancer cell death in vivo
Zhang, L., Jing, D., Jiang, N., Rojalin, T., Baehr, C. M., Zhang, D., Xiao, W., Wu, Y., Cong, Z., Li, J. J., et al. (2020) · Nature Nanotechnology · doi:10.1038/s41565-019-0626-4 · Cited by 273
Protein kinase inhibitors: contributions from structure to clinical compounds
Johnson, L. N. (2009) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583508004745 · Cited by 264
The molecular circuitry of brassinosteroid signaling
Belkhadir, Y., & Jaillais, Y. (2015) · New Phytologist · doi:10.1111/nph.13269 · Cited by 253
A Dimeric PINK1-containing Complex on Depolarized Mitochondria Stimulates Parkin Recruitment
Okatsu, K., Uno, M., Koyano, F., Go, E., Kimura, M., Oka, T., Tanaka, K., & Matsuda, N. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.509653 · Cited by 259
The Mad2 Conformational Dimer: Structure and Implications for the Spindle Assembly Checkpoint
Mapelli, M., Massimiliano, L., Santaguida, S., & Musacchio, A. (2007) · Cell · doi:10.1016/j.cell.2007.08.049 · Cited by 243
Tailoring T-cell receptor signals by proximal negative feedback mechanisms
Acuto, O., Bartolo, V. D., & Michel, F. (2008) · Nature reviews. Immunology · doi:10.1038/nri2397 · Cited by 245
Abscisic acid perception and signaling: structural mechanisms and applications
Ng, L. M., Melcher, K., Teh, B. T., & Xu, H. E. (2014) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.5 · Cited by 249
Bronchial and Peripheral Murine Lung Carcinomas Induced by T790M-L858R Mutant EGFR Respond to HKI-272 and Rapamycin Combination Therapy
Li, D., Shimamura, T., Ji, H., Chen, L., Haringsma, H. J., McNamara, K. L., Liang, M., Perera, S. A., Zaghlul, S., Borgman, C. L., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.06.005 · Cited by 243
The ERBB3 receptor in cancer and cancer gene therapy
Sithanandam, G., & Anderson, L. M. (2008) · Cancer Gene Therapy · doi:10.1038/cgt.2008.15 · Cited by 240
Ligand-Specific c-Fos Expression Emerges from the Spatiotemporal Control of ErbB Network Dynamics
Nakakuki, T., Birtwistle, M. R., Saeki, Y., Yumoto, N., Ide, K., Nagashima, T., Brusch, L., Ogunnaike, B. A., Okada, M., & Kholodenko, B. Ν. (2010) · Cell · doi:10.1016/j.cell.2010.03.054 · Cited by 241
Crosstalk between Arg 1175 methylation and Tyr 1173 phosphorylation negatively modulates EGFR-mediated ERK activation
Hsu, J.-M., Chen, C., Chou, C., Kuo, H.-P., Li, L., Lin, C.-Y., Lee, H.-J., Wang, Y., Liu, M., Liao, H.-W., et al. (2011) · Nature Cell Biology · doi:10.1038/ncb2158 · Cited by 244
International Union of Basic and Clinical Pharmacology. XC. Multisite Pharmacology: Recommendations for the Nomenclature of Receptor Allosterism and Allosteric Ligands
Christopoulos, A., Changeux, J., Catterall, W. A., Fabbro, D., Burris, T. P., Cidlowski, J. A., Olsen, R. W., Peters, J. A., Neubig, R. R., Pin, J., et al. (2014) · Pharmacological Reviews · doi:10.1124/pr.114.008862 · Cited by 246
Structure and function of VEGF receptors
Stuttfeld, E., & Ballmer‐Hofer, K. (2009) · IUBMB Life · doi:10.1002/iub.234 · Cited by 253
The Chemical Biology of Protein Phosphorylation
Tarrant, M. K., & Cole, P. A. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.070907.103047 · Cited by 238
Self-citation
Structural Basis for the Inhibition of Tyrosine Kinase Activity of ZAP-70
Deindl, S., Kadlecek, T. A., Brdička, T., Cao, X., Weiss, A., & Kuriyan, J. (2007) · Cell · doi:10.1016/j.cell.2007.03.039 · Cited by 240
Self-citation
Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma
Bresler, S. C., Wood, A., Haglund, E. A., Courtright, J., Belcastro, L. T., Plegaria, J. S., Cole, K. A., Toporovskaya, Y., Zhao, H., Carpenter, E. L., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002950 · Cited by 242
p95HER2 and Breast Cancer
Arribas, J., Baselga, J. M., Pedersen, K., & Parra-Palau, J. L. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3795 · Cited by 241

Authors: Zhang, X., Gureasko, J., Shen, K., Cole, P. A., & Kuriyan, J.
Affiliations: Howard Hughes Medical Institute (US)
Johns Hopkins University (US)
Corresponding author: Kuriyan, John
ORCID: Zhang, Xuewu
Shen, Kui
Cole, Philip A.
Kuriyan, John
Venue: Cell
Publisher: Elsevier BV
Published: 2006-06
Volume: 125
Issue: 6
Pages: 1137-1149
ISSN: 0092-8674 (ISSN-L)
DOI: 10.1016/j.cell.2006.05.013
OpenAlex: W2100794900
Cited by: 1,650
References: 42
Citations by year: 2026: 81 · 2025: 70 · 2024: 67 · 2023: 91 · 2022: 76 · 2021: 75 · 2020: 83 · 2019: 77 · 2018: 78 · 2017: 60 · 2016: 66 · 2015: 103 · 2014: 120 · 2013: 95 · 2012: 76
FWCI: 40.87
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 2639 d)
Locations: Cell (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (R01-CA74305, R01CA096504, R01-CA96504, R01CA074305)
Topics: Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords: epidermal growth factor receptor, allosteric activation, autoinhibition, receptor dimerization, activation loop, asymmetric dimer, cyclin-dependent kinases, Src kinase, C-terminal lobe, receptor tyrosine kinase
MeSH terms: Allosteric Regulation, Amino Acid Sequence, Animals, Enzyme Activation, Humans, Leucine, Models, Molecular, Molecular Sequence Data, Mutation, Phosphorylation, Protein Conformation, Protein Structure, Tertiary, Crystallography, X-Ray, Cyclin-Dependent Kinases, src-Family Kinases, Dimerization, NIH 3T3 Cells, Mice, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks